Hence, our plan was to employ a designed CEA-binding protein (CEABP) to fuse with the p28-p53 protein in order to specifically recognize CRC cells in vivo to deliver the p53 protein in a targeted manner to prevent CRC tumor growth (Figure 4A). The gene discussed is TP53; the disease is neoplasm.